Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Eisai and Bial partner for European commercialization of Zebinix

Feb. 20, 2009

sanofi-aventis imparts new cannabinoid CB2 receptor antagonists for pain relief

Feb. 20, 2009

New gamma-secretase inhibitors reported in recent Schering-Plough patent

Feb. 20, 2009

AVI BioPharma treats first patient in AVI-4658 Duchenne muscular dystrophy trial

Feb. 20, 2009

TRPV1-mediated analgesic activity is enhanced by repeated administration of ABT-102

Feb. 20, 2009

FDA extends Hemispherx's NDA review date for Ampligen in CFS

Feb. 19, 2009

FDA sets PDUFA date for review of Zogenix's NDA for migraine drug Sumavel DosePro

Feb. 19, 2009

Phase III SOFIA study does not achieve primary endpoint in autistic disorder

Feb. 19, 2009

Pharmos agrees to sell PRS-639058 and other CB2 agonists to Reperio

Feb. 19, 2009

Cipher receives tentative FDA approval for extended-release tramadol

Feb. 18, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...